Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis. The company also develops STAT6, a type 2 inflammation in allergic and atopic diseases; and TYK2 to treat autoimmune and inflammatory diseases. The company has a strategic alliance with Sanofi S.A. for the development of drug candidates targeting IRAK4 outside of the oncology and immuno-oncology fields. Kymera Therapeutics, Inc. was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Metrics to compare | KYMR | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipKYMRPeersSector | |
---|---|---|---|---|
P/E Ratio | −11.7x | −1.1x | −0.5x | |
PEG Ratio | 0.50 | −0.06 | 0.00 | |
Price/Book | 3.6x | 2.2x | 2.6x | |
Price / LTM Sales | 47.7x | 9.2x | 3.3x | |
Upside (Analyst Target) | 46.9% | 328.8% | 43.4% | |
Fair Value Upside | Unlock | 7.2% | 7.1% | Unlock |